Although the underlying molecular mechanism of the KLF14 agonist perhexiline in sepsis was not elucidated in our study, we believe that KLF14 is a potential new therapeutic target for human sepsis, and related clinical trials are warranted. This evidence concerns the gene KLF14 and Sepsis.